The relative simplicity of the micronucleated erythrocyte endpoint has made it amenable to automated scoring approaches. Flow cytometry is one such scoring platform that has been employed successfully. This review describes the evolution and properties of flow cytometry-based scoring of micronucleated erythrocytes. The methodology has become widely applied to rodent blood specimens and the high throughput nature of the technology provides a number of advantages over manual microscopic scoring. For instance, the ability to efficiently survey many dose levels and many more cells per specimen relative to microscopy benefits studies that are designed to identify no observable effect levels or lowest observable effect levels. Furthermore, flow cytometry makes it practical to study species with low spontaneous reticulocyte (RET) counts and micronucleus (MN) frequencies, thereby facilitating integration of blood-based micronucleated reticulocyte (MN-RET) frequency measurements into experiments conducted across species of toxicological interest. This capability enhances genotoxicity assessments that have historically been made in dedicated MN tests performed in one species. Importantly, the feasibility of using MN-RET frequencies in blood from humans as an index of genetic damage in bone marrow opens a critical area of application that had not been practical previously. We conclude with recommendations for additional work that is needed to more fully realise the potential of flow cytometric in vivo MN scoring.
The relative simplicity of the micronucleated erythrocyte endpoint has made it amenable to automated scoring approaches. Flow cytometry is one such scoring platform that has been employed successfully. This review describes the evolution and properties of flow cytometry-based scoring of micronucleated erythrocytes. The methodology has become widely applied to rodent blood specimens and the high throughput nature of the technology provides a number of advantages over manual microscopic scoring. For instance, the ability to efficiently survey many dose levels and many more cells per specimen relative to microscopy benefits studies that are designed to identify no observable effect levels or lowest observable effect levels. Furthermore, flow cytometry makes it practical to study species with low spontaneous reticulocyte (RET) counts and micronucleus (MN) frequencies, thereby facilitating integration of blood-based micronucleated reticulocyte (MN-RET) frequency measurements into experiments conducted across species of toxicological interest. This capability enhances genotoxicity assessments that have historically been made in dedicated MN tests performed in one species. Importantly, the feasibility of using MN-RET frequencies in blood from humans as an index of genetic damage in bone marrow opens a critical area of application that had not been practical previously. We conclude with recommendations for additional work that is needed to more fully realise the potential of flow cytometric in vivo MN scoring.
Significant achievements
The importance of evaluating breakage, loss or rearrangements of chromosomes, and/or DNA damage leading to these events, has been recognised from the earliest days of the field of genetic toxicology (1) (2) (3) . The classical method of evaluating these types of damage is the microscopic evaluation of metaphase chromosomes (4) , but this method is timeconsuming, labour-intensive, and the requirement to obtain metaphase cells after exposure to suspect agents often precludes its application in tissues in vivo. The work of Matter and Schmid (5), Heddle (6), Countryman and Heddle (7) and Heddle et al. (8) in the early 1970s showed that the formation of micronuclei (MN) in newly formed rodent bone marrow erythrocytes or in cultured human lymphocytes provided convenient indices of these events that were much more easily and rapidly scored than the conventional cytogenetic chromosome analysis. Subsequent studies showed a close correlation between the induction of chromosomal aberrations and MN (9, 10) .
When regulatory requirements for evaluation of genetic damage were introduced in the 1970s, the testing requirements included evaluation of cytogenetic damage in rodent bone marrow. The technical advantages and simplicity of the bone marrow erythrocyte MN assay quickly led to it becoming the most commonly used assay for in vivo evaluation of this type of damage in regulatory practice. These advantages include the greater ease of scoring and increased statistical power of the MN index relative to chromosomal analysis as a result of the ease of evaluating larger numbers of cells, as well as defined cell maturation kinetics that allows selective scoring of the newly formed erythrocytes after one to two divisions following exposure (in which the MN frequency is at its highest value).
It was initially thought that the in vivo erythrocyte assay would be limited to bone marrow because early work suggested that induced frequencies were greater in bone marrow than in peripheral blood (11) and because it was known that in many species, there was selective splenic removal of MN-containing erythrocytes from the peripheral blood circulation. However, it was subsequently shown that there was little selective removal of MN-erythrocytes from the peripheral circulation of mice (12) . The many advantages of being able to conduct this assay using microliter quantities of peripheral blood rather than sacrificing animals to obtain bone marrow led to the increasing use of blood as the tissue of choice in studies with the mouse and acceptance of this assay for regulatory studies (13) (14) (15) (16) . Additionally, the potential to automate scoring of peripheral blood samples was recognised immediately, due to the uniformity of erythrocytes in peripheral blood and the relative lack of nucleated cells, mast cell granules and other potentially confounding particles (12) .
There were several early attempts at automatically scoring the frequency of MN-erythrocytes. Strategies based on enrichment of erythrocytes and/or reticulocytes (RETs) by density gradient centrifugation followed by image analysis of stained slides (17, 18) and flow cytometric analysis of fixed peripheral blood samples were employed (19) (20) (21) (22) (23) . These early efforts demonstrated the feasibility of using a flow cytometric platform but did not allow separate analysis of RETs and mature red blood cells, thus limiting the utility of the assays, and the image analysis methodology did not achieve the simplicity and scoring speed that could potentially be achieved by flow cytometry.
A significant advance in the field occurred when Grawé et al. (24) reported a dual-dye (Hoechst/thiazole orange) technique that made it possible to determine the frequency of micronucleated reticulocytes (MN-RETs) in mouse blood. The importance of separately scoring MN in RETs is that only this erythrocyte subpopulation, not the total erythrocyte pool, is responsive to acute genotoxicant exposures. Since in vivo rodent MN tests have historically been dominated by acute exposure study designs, the ability to automate MN-RET scoring was a major advance. However, the requirement for a relatively rare dual-laser flow cytometer capable of providing ultraviolet excitation restricted the adoption of the technique to research settings. Eventually, a simple and reliable single-laser flow cytometric method using antibodies against the CD71-defined antigen (transferrin receptor) was developed to overcome this limitation (25, 26) . Briefly, this methodology involves adding fixed whole blood (or column fractionated bone marrow) to a labelling solution that simultaneously exposes cells to anti-CD71-FITC, an anti-platelet-specific antibody (anti-CD61-PE) and RNase. After an adequate incubation period, the cells are resuspended in a propidium iodide-containing buffer and are thereafter ready for flow cytometric analysis. Given the flexibility that exists with the choice of fluorochrome-antibody conjugates, this labelling strategy provided the means to perform MN frequency measurements in the most recently formed fraction of erythrocytes (i.e. RETs) using widely available single-laser flow cytometers.
The anti-CD71-based method described above has been configured into commercially available kit format (In Vivo MicroFlowÒ; Litron Laboratories, Rochester, NY, USA) and has been adopted widely by the genetic toxicology research and product safety assessment communities (27) (28) (29) (30) (31) (32) (33) (34) (35) . The success and adoption of this methodology can be attributed in part to inter-laboratory validation efforts that have established the high portability of the technique (36, 37) . For instance, a 14 laboratory international research effort evaluated the flow cytometric mouse peripheral blood method using coded samples and quality-assured reagents and instructions. An important component of the supplied kits was a malaria biostandard-that is, fixed erythrocytes from rodents that had been infected with Plasmodium berghei (21, 38) . Whereas MN are rare and variable in size, the DNA content of P.bergheiinfected erythrocytes is uniform and depending on the degree of infection, have a high prevalence. These MN-mimicking cells enabled each laboratory to consistently and reliably configure their flow cytometers and define the size range of MN being scored (see Figure 1 ). The high number of cells evaluated (i.e. 20 000 RETs per blood sample was used in this validation study) provided 10-to 20-fold the number of cells normally scored using microscopy. This study demonstrated that the standardised kit-formatted reagents, including the malaria biostandard, and the ability to score higher numbers of cells were important advances that minimised inter-and intralaboratory variability.
A second phase of this inter-laboratory study demonstrated good agreement between flow cytometry-and microscopybased measurements, with close agreement between specimens analysed by flow cytometry at two independent sites (r s 5 0.857, n 5 248). Results of this second phase of the validation effort provided convincing evidence that the overall performance of mouse peripheral blood MN-RET analyses was enhanced by the use of flow cytometry-based methodology.
Even as validation work with mouse blood proceeded, it became clear that the ability to focus analysis on peripheral blood RETs had important implications for applying the scoring technique to other species of toxicological interest. For example, although flow cytometric methods initially focused on mouse blood, other investigators were evaluating the feasibility of using rat peripheral blood specimens as the basis of in vivo MN tests (17) . This was an important line of investigation since rats are the animal for which most general toxicological, pharmacologic and toxicokinetic data are available. So, although it was recognised that rats, unlike mice, selectively remove MN-erythrocytes from the peripheral circulation (39) , collaborative studies by The Collaborative Study Group for the Micronucleus Test, The Mammalian Mutagenesis Study Group of the Japanese Environmental Mutagen Society (CSGMT/JEMS/MMS) systematically investigated the utility of the rat blood compartment (40) . Rat bone marrow and peripheral blood were studied for 40 model chemicals with known carcinogenicity and mutagenicity assay outcomes, including known clastogens and aneugens and some with species differences between rats and mice. Among 36 mouse MN-positive rat carcinogens, 33 were found to be positive and 3 negative in rat bone marrow. In addition, 30 were positive, 3 equivocal and 3 negative in rat peripheral blood. While several chemicals gave unexpected results, overall concordance between rat bone marrow and rat peripheral blood was 92%, and concordance between mouse and rat erythrocytes was 88%. Based on these results, the group concluded that the rat MN assay, using either bone marrow or peripheral blood, could be used as an alternative to the mouse MN assay.
Following up on this evidence that both rat blood and bone marrow could be used in the MN assay, further studies were performed to investigate the possibility of integrating the MN endpoint into general toxicology studies. The CSGMT/JEMS/ MMS organised an expanded collaborative study on the rat MN assay using a 28-day repeat-dose treatment schedule of 15 model chemicals with different modes of action (41) . A majority of these compounds gave positive results within the estimated dose range of a general toxicological study. These results indicated that rats can provide biologically important and relevant information regarding the genotoxic potential of chemicals and supported the integration of the MN endpoint into ongoing rat toxicology studies. Such an integration strategy is important for animal welfare since it can reduce animal use in preclinical safety studies. This topic was discussed in the revision of guidance by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (42) and also at the workshop on 'Reduction of Use of Animals in Regulatory Genotoxicity Testing: Identification and Implemen-
The development of a highly transferable flow cytometric technique, coupled with the demonstration that rat blood could be used effectively to investigate genotoxicant-induced MN-RET, led to a series of collaborative studies that evaluated the feasibility of monitoring chromosomal damage in the peripheral blood of the key species used in research and regulatory safety studies-the rat, beagle dog and nonhuman primates. These studies were organised by the US Food and Drug Administration and evaluated MN-RET frequencies in peripheral blood and bone marrow samples from the Sprague-Dawley rats, beagle dogs and rhesus monkeys exposed to clastogens and/or aneugens using blinded replicate samples and three different analytical methods. The analytical methods used were (i) flow cytometric analysis with anti-CD71 labelling to distinguish newly-formed RETs (26), (ii) conventional microscopic scoring of methanol-fixed slides with acridine orange staining (44) and (iii) supravital staining with acridine orange to distinguish newly formed RETs (45, 46) . The main objectives were to compare the relative sensitivity of bone marrow versus peripheral blood MN-RET frequencies for monitoring chromosomal damage and to compare the sensitivity and intra-and inter-laboratory variability of results obtained by each of the three analytical methods. In all three species, the MN-RET frequency in peripheral blood reflected the bone marrow MN-RET frequencies (47) (48) (49) . The rat was the most intensively studied (47) , and in this species, the effect of spleen function was determined directly by comparison of normal versus splenectomised animals. More limited data in the beagle dog (48) and non-human primate (49, 50) suggest that these species are similarly suitable. In the rat, although the observed genotoxicant-induced increase in MN frequency is lower in peripheral blood relative to bone marrow, the enhanced precision and statistical power of the flow cytometric analysis of blood allows equal or better sensitivity compared with traditional microscopic analysis of bone marrow. The results clearly demonstrated an analytical advantage of flow cytometric scoring over microscopy, with considerably lower inter-and intra-laboratory variation and higher statistical sensitivity. Taken together, the data support the integration of the peripheral blood MN-RET endpoint into routine toxicity studies in rats or mice, eliminating the need for a separate bioassay to evaluate chromosomal damage in bone marrow. This has been accepted as a regulatory alternative in mice (13, 16) and has been proposed for acceptance in rats (42) .
MN assessments conducted with human blood specimens have traditionally focused on ex vivo peripheral blood lymphocyte cultures that have been stimulated to divide with mitogens (51) . MN have also been measured in human erythrocyte populations to evaluate cytogenetic damage resulting from chemo-or radiotherapy and to investigate associations between nutritional or lifestyle factors and cytogenetic damage (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) . These human erythrocyte studies have primarily been performed with bone marrow aspirates or with peripheral blood from splenectomised subjects. Prior focus on splenectomised subjects is related to the fact that, as with the non-mouse species described above, the human spleen efficiently removes MN-containing erythrocytes from peripheral blood circulation. Even so, data suggest that flow cytometry represents a means of overcoming obstacles to human blood-based analyses. For instance, Abramsson-Zetterberg et al. (62) and Offer et al. (63) have described procedures for physically enriching immature (CD71-positive) RETs via magnetic column separation, followed by staining that provides MN-RET frequency measurements. Using physical enrichment approaches, Grawé et al. (64) reported that peripheral bloodmicronucleated CD71-positive RET frequencies tended to peak 72 h following exposure to radioactive iodine, while nearbaseline values were observed at 96 h ( 131 I, thyroid cancer patients, n 5 44).
Using a human whole blood procedure similar to that described for rodent specimens, Dertinger et al. have demonstrated that CD71-positive RET analyses mitigate against the muting effect that splenic filtration has on genotoxicant-induced MN-RET yields (65, 66) . Using this technique, Witt et al. (67) studied MN-RET frequencies in human immunodeficiency virus-infected mothers as well as their newborn infants. Treatment with zidovudine was associated with .10-fold higher MN-RET values in mothers as well as infants. More recently, two studies report that patients undergoing treatment with hydroxyurea for sickle-cell disease exhibit elevated MN-RET frequencies (68, 69) . These zidovudine and hydroxyurea studies exemplify situations where rodent data were extremely useful, but a much fuller understanding of genotoxic risk was achieved by studying the human in the context of actual exposure scenarios.
In addition to making MN-RET measurements more objective and practical to perform across species, flow cytometry-based analysis provides additional advantages. For example, it allows investigators to evaluate whether treatmentinduced MN are the result of clastogenic or aneugenic activity-i.e. whether the MN arise from chromosomal fragments or from the loss of whole chromosomes. This mode of action information is based on the nucleic acid dye-associated fluorescence intensity of MN-RET, a measurement that is directly related to DNA content. Since clastogenic agents generate MN composed mainly of chromosome fragments, and aneugens give rise to whole chromosome-containing MN, a means for discriminating mode of action is derived from nucleic acid fluorescence profiles. So while anti-CREST antibodies or FISH-based analyses can more definitively elucidate genotoxic mode of action, Torous et al. (70) and also Witt et al. (32) have demonstrated that flow cytometry can differentiate these modes of action in the normal conduct of the assay, without the requirement for additional reagents or equipment.
Another benefit derived from the high throughput capacity of flow cytometry is that it allows investigators to more effectively study dose-response relationships. Since the number of cells scored per subject is increased, it becomes practical to expand the number of dose levels studied. For instance, using flow cytometry, Asano et al. (71) characterised the low end of the mitomycin C, Ara-C and colchicine doseresponse curves by studying 5-6 dose levels, examining 10 6 RETs per rodent. Interestingly, these investigators observed what they termed a 'practical threshold' for clastogenic as well as the aneugenic compounds. This investigation represents a good example of flow cytometry transforming the MN assay from a hazard identification tool to one that can support risk assessment models that benefit from careful quantitative examination of dose-response relationships, especially at low, often more relevant dose levels.
Knowledge gaps and recommendations for future research
Laboratory rodent models Flow cytometric analysis of rodent blood MN-RET is a relatively mature technology that is likely to find even wider use, especially with the new emphasis on integrating genetic toxicology endpoints into on-going toxicology studies. This is predicted to fuel adoption of flow cytometric scoring, especially for rat blood where the incidence of RETs and MN-RETs is sufficiently low that the assay benefits considerably from the ability to interrogate many thousands of cells per second (72) . As more integrated studies are performed, data will accumulate that should help practitioners more thoroughly understand how these experimental designs affect the MN-RET endpoint. One example is dose spacing, which is typically broader in general toxicology studies compared to dedicated MN tests. As data accumulate, these and other parameters should be re-evaluated to ensure that assay sensitivity is not adversely affected as the benefits of integration are realised.
As discussed herein, the throughput capacity of flow cytometry has the potential to support experimental designs that contribute to risk assessments. Transitioning the MN-RET endpoint from one of hazard identification to risk assessment will benefit from further research that defines the minimal number of dose levels, animals per group and cells that should be scored. On a related point, there is a need for consensus on statistical approaches for characterising dose-response relationships and for deriving acceptable margins of exposure.
Other animal models As discussed above, there is evidence that flow cytometric scoring of canine and non-human primate blood MN-RET reflects bone marrow genotoxicity. This makes it practical to study the DNA damaging potential of a chemical or other agent across the major animal species of toxicological interest (mouse, rat, beagle dog and non-human primate). This could be important in situations, for instance, where human deposition and/or metabolism is not adequately approximated by rodents. However, while proof-of-principle studies have yielded encouraging results, data for these species remain scant. This area would benefit from studies with additional chemicals and acute as well as protracted dosing schedules in order to better understand the merits and limitations of these models. For instance, to our knowledge, there are no published reports of blood MN-RET frequencies in dogs or non-human primates following exposure to an aneugenic agent.
Although we have focused on preclinical models designed to evaluate human health effects, environmental studies that involve sentinel species, for instance wild or feral rodents, may also benefit from flow cytometric MN-RET scoring (73) . As these studies will often involve relatively subtle/moderate exposures, the assessment of many cells per individual for MN-RET frequency has the potential to improve these studies in a fundamental way. However, this is also an area that would benefit from further work with prototypical clastogens and aneugens so that the sensitivity of different species is better understood. Furthermore, for each species being considered, it is important to develop a firm understanding of the degree to which spleen function affects MN frequencies (74) . several different genotoxic agents, and these results suggest the endpoint could be valuable in a number of situations. Applications include, but are not limited to: (i) assessing the genotoxic potential of pharmaceuticals undergoing human clinical trials; (ii) identifying polymorphisms or epigenetic effects that may lead to hypersensitivity to particular genotoxicants; (iii) evaluating compounds, diets or other factors that may protect against endogenous or xenobioticinduced genetic damage; (iv) determining the level of DNA damage in a population following accidental exposures and (v) monitoring workers who may be occupationally exposed to genotoxic materials.
Human studies
In order for the endpoint to find greater use and more widespread application, several types of data are needed. First, it would be valuable to have a deeper understanding of the kinetics by which genotoxicant-induced MN-RET appear in peripheral blood circulation and the degree to which exposure level or other variables that influence erythropoiesis affect the kinetics. This may be especially important for studies that involve acute exposures. Second, although inter-laboratory data based on rodent specimens suggest the flow-cytometric MN-RET scoring is highly transferable, the human data published to date have been generated by a small number of laboratories. Since human specimens tend to exhibit lower CD71-positive RET and MN-RET frequencies, inter-laboratory studies that assess portability of the method should be performed. Third, the experimental design of any type of human MN-RET investigation would benefit from additional data that better describe intra-and inter-subject variability. This information is needed so that future studies are designed with sufficient power. Fourth, a better understanding of lifestyle and genotype factors that influence spontaneous MN-RET values is needed. Factors such as age and micronutrient status have been well studied for the lymphocyte-cytokinesis block MN assay (75) , and some work has been performed with the MNerythrocyte endpoint in splenectomised subjects (56, 57, 59) , but this type of information is sparse for MN-RET in cases where spleen function is normal (63, 76) . Fifth, the influence that certain common pathophysiological states and/or prescribed drugs have on MN-RET frequencies should be investigated for their effect on MN-RET. For instance, it is conceivable that disease states that affect micronutrient status or that cause chronic inflammation may influence MN-RET frequency. Identification of confounders is obviously important for statistical models, and they also can serve a role in study enrollment criteria.
Communication
As with other endpoints that have been developed for broad dissemination and regulatory use, an on-going task for developers and practitioners of flow cytometric MN-RET scoring includes education. This phase of work, in conjunction with continued research as described herein, is important so that the wealth of data generated by flow cytometric analyses is interpreted appropriately. We view this special anniversary issue on MN as an important opportunity to advance this aspect of the work.
